Table 2 NCV studies in clinical development trial
From: The perfect personalized cancer therapy: cancer vaccines against neoantigens
Clinical trial | Cancer | Intervention | vaccine | status |
|---|---|---|---|---|
NCT01885702 | Colorectal Cancer | DC vaccination | DC | Active, not recruiting |
NCT02632019 | Biliary tract tumor | DC vaccination and gemcitabine | DC | Unknown status |
NCT02956551 | Lung cancer | DC vaccination | DC | Not yet recruiting |
NCT03122106 | Pancreatic Cancer | Neoantigen DNA vaccine with electroporation | DNA | Recruiting |
NCT03199040 | Triple Negative Breast Cancer | Neoantigen DNA vaccine and Durvalumab | DNA | Not yet recruiting |
NCT01970358 | Melanoma | Peptides with Poly-ICLC | peptide | Active, not recruiting |
NCT03068832 | Pediatric Brain Tumor | Peptide vaccine with Poly ICLC | peptide | Not yet recruiting |
NCT02287428 | Glioblastoma | NeoAntigen Vaccine and Radiation Therapy | peptides | Active, not recruiting |
NCT02897765 | Many | NEO-PV-01 and Nivolumab | peptides | Recruiting |
NCT02950766 | Kidney Cancer | Drug: NeoVax|Drug: Ipilimumab | peptides | Not yet recruiting |
NCT03166254 | Lung Cancer | Long peptide with Poly ICLC and Pembrolizumab | Peptides | Not yet recruiting |
NCT03219450 | Lymphocytic Leukemia | NeoVax with Cyclophosphamide | peptides | Not yet recruiting |
NCT03359239 | Urothelial Bladder Cancer | Peptides with Poly ICLC and Atezolizumab | peptides | Not yet recruiting |
NCT03361852 | Follicular Lymphoma | Neo Vax and Rituximab | peptides | Not yet recruiting |
NCT03380871 | Lung Cancer | NEO-PV-01 Pembrolizumab Carboplatin Pemetrexed | peptides | Not yet recruiting |
NCT03422094 | Glioblastoma | NeoVax and Nivolumab Ipilimumab | Peptides | Not yet recruiting |
NCT03289962 | Many | Drug: RO7198457|Drug: Atezolizumab | RNA | Recruiting |
NCT02992977 | many | AutoSynVax TM vaccine | HSP Peptides | Active, not recruiting |